SCHEMBL7345019

SCHEMBL7345019

COc1ccc2ccc(C#N)cc2c1OCC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
ABCB1 P08183 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
NCEH1 Q6PIU2 2/20 0.36
TNFRSF1A P19438 1/20 0.36
AR P10275 1/20 0.36
LMNA P02545 1/20 0.36
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
NR3C2 P08235 1/20 0.36
PDE5A O76074 3/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7445501 0.88 PLAU (0.50) PLAUL3MBTL1USP2MAPTHPGD
SCHEMBL7340884 0.84 HPGD (0.53) PLAUUSP2MAPTHPGDPTGDR2
SCHEMBL12145823 0.78 AR (0.45) L3MBTL1ABCB1PTGDR2ARNR3C1
SCHEMBL7337530 0.76 AR (0.46) MAPTNCEH1ARPDE5A
SCHEMBL13665119 0.75 ALDH1A1 (0.47) L3MBTL1HPGDARNPC1TP53
SCHEMBL1369812 0.74 PTGDR2 (0.47) USP2MAPTHPGDABCB1PTGDR2
SCHEMBL7351841 0.73 MYB (0.45) PLAUMAPTHPGDARPDE5A
SCHEMBL12147475 0.73 MAPT (0.50) L3MBTL1MAPTRAB9A
Hydrochloric Acid SCHEMBL7343861 0.72 PLAU (0.59) PLAUL3MBTL1MAPTHPGDNCEH1
SCHEMBL16110360 0.72 MTNR1A (0.51) USP2MAPTMTNR1AMTNR1BABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885L3MBTL1 1892/4885USP2 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.